Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL ...

Bristol-Myers Squibb's HDAC inhibitor Istodax has been on the US market for a decade as a treatment for peripheral T-cell lymphoma (PTCL), but will now be withdrawn from sale after a failed phase ...

Clinicians can expect to see topline results following the conclusion of the trial. “HDAC inhibitors, and with that CS014 as an innovative development in this field, could represent a ...

The company has also made significant progress in its glioblastoma treatment trials and has secured a patent for selective histone deacetylase (HDAC) inhibitors, a noteworthy advancement in its ...

Currently, Regenacy is seeking additional partnerships to develop its portfolio of HDAC inhibitors. Recently, the company announced a collaboration with the Charcot–Marie–Tooth Association ...

“Understanding whether or not these HDAC inhibitors could be an interesting novel therapeutic angle to go after. I think that would be really exciting,” Liddelow added. Paul Tesar cofounded Convelo ...

Additionally, the platform supports combination therapies using hedgehog pathway inhibitors alongside HDAC inhibitors to amplify anti-cancer effects. “This new patent for our oncology ...

Its pipeline would be headed by ALKS 2680, an orexin 2 receptor agonist for the treatment of narcolepsy that is building towards the start of clinical testing next year, plus HDAC inhibitors for ...

The planned registrational Phase 3 study of eRapa in FAP will be a double-blind placebo-controlled trial in 168 patients, randomized 2:1 drug / placebo. It is expected the study will be conducted in ...